Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Otsuka Pharmaceutical, Acucela deal

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Acucela Inc. (Tokyo:4589), Seattle, Wash. Business: Ophthalmic Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucelas emixustat (ACU-4429) and …

    Published on 6/20/2016
  • Pfizer, Shire deal

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Autoimmune Shire licensed worldwide rights to Pfizers PF-00547659. The anti-human mucosal addressin cell adhesion …

    Published on 6/20/2016
  • Teva, Dr. Reddys Laboratories Ltd., Allergan deal

    Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Allergan plc (NYSE:AGN), Dublin, Ireland Business: Generics Teva agreed to sell a portfolio …

    Published on 6/20/2016
  • Afferent, Merck deal

    Afferent Pharmaceuticals Inc., San Mateo, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Pulmonary Merck will acquire Afferent for $500 million in cash and up to $750 million in clinical and …

    Published on 6/13/2016
  • Amyris, J&J deal

    Amyris Inc. (NASDAQ:AMRS), Emeryville, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Pharmaceuticals Amyris and Johnson & Johnsons Janssen Biotech Inc. unit partnered to discover and develop a …

    Published on 6/13/2016
  • Bellicum, Leiden University Medical Center deal

    Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), Houston, Texas Leiden University Medical Center, Leiden, the Netherlands Business: Cancer Bellicum and the center partnered to discover and validate high-affinity T cell …

    Published on 6/13/2016
  • Botulinum Toxin Research, Revance deal

    Botulinum Toxin Research Associates Inc., Quincy, Mass. Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Business: Neurology, Dermatology, Inflammation Botulinum Toxin Research granted Revance IP related to …

    Published on 6/13/2016
  • CrystalGenomics, Aptose Biosciences deal

    CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Aptose Biosciences Inc. (TSX:APS;NASDAQ:APTO), Toronto, Ontario Business: Cancer CrystalGenomics granted Aptose an exclusive option to license rights to …

    Published on 6/13/2016
  • Eisai, Novartis deal

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer Eisais Eisai Inc. subsidiary and Novartis Novartis Pharmaceuticals Corp. affiliate partnered to co-promote …

    Published on 6/13/2016
  • EpimAb Biotherapeutics, Innovent Biologics deal

    EpimAb Biotherapeutics Inc., Shanghai, China Innovent Biologics Inc., Suzhou, China Business: Antibodies EpimAb granted Innovent rights to Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop bispecific antibodies…

    Published on 6/13/2016
  • Excelra, Astellas deal

    Excelra Knowledge Solutions Pvt. Ltd., Hyderabad, India Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmaceuticals, Bioinformatics Excelra and Astellas partnered to use Excelras Drug Repurposing Platform …

    Published on 6/13/2016
  • Foundation Medicine, AstraZeneca deal

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Pharmacogenetics Foundation and AstraZeneca partnered to develop a companion diagnostic assay for AZs …

    Published on 6/13/2016
  • Genisphere, AstraZeneca deal

    Genisphere LLC, Hatfield, Pa. AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cancer, Drug delivery Genisphere and AstraZenecas MedImmune LLC unit partnered to develop nanoparticles to treat cancer. …

    Published on 6/13/2016
  • Guided Therapeutics, Shenguo Medical deal

    Guided Therapeutics Inc. (OTCBB:GTHP), Norcross, Ga. Shenghuo Medical LLC, Business: Diagnostic Guided Therapeutics granted Shenghuo exclusive rights to manufacture and commercialize LuViva Advanced Cervical Scan and …

    Published on 6/13/2016
  • Kyowa Hakko Kirin, Medgenics deal

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Medgenics Inc. (NYSE-M:MDGN), Wayne, Pa. Business: Autoimmune, Gastrointestinal Kyowa granted Medgenics an exclusive option to license exclusive rights in the U.S. …

    Published on 6/13/2016
  • Mayo Clinic, TapImmune deal

    Mayo Clinic, Rochester, Minn. TapImmune Inc. (OTCQB:TPIV), Jacksonville, Fla. Business: Cancer TapImmune exercised an option under a 2010 deal with Mayo to license exclusive, worldwide rights to develop and …

    Published on 6/13/2016
  • Orion, Bayer deal

    Orion Corp. (HSE:ORNAV;HSE:ORNBV), Espoo, Finland Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cancer The partners added the joint development of Orions ODM-201 to treat metastatic hormone-sensitive prostate …

    Published on 6/13/2016
  • Seres Therapeutics, Mayo Clinic deal

    Seres Therapeutics Inc. (NASDAQ:MCRB), Cambridge, Mass. Mayo Clinic, Rochester, Minn. Business: Hepatic Seres and Mayo Clinics Center for Individualized Medicine partnered to identify microbiome therapeutics for primary…

    Published on 6/13/2016
  • Sorrento, 3SBio deal

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. 3SBio Inc. (HKSE:1530), Shenyang, China Business: Cancer Sorrentos TNK Therapeutics Inc. subsidiary and 3SBio formed a JV focused on chimeric antigen receptor…

    Published on 6/13/2016
  • Takeda, Roivant Sciences deal

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Roivant Sciences Ltd., Hamilton, Bermuda Business: Cancer, Genitourinary, Endocrine/Metabolic Takeda and Roivant launched Myovant Sciences Ltd. Takeda granted …

    Published on 6/13/2016
  • Takeda, Ultragenyx deal

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Novato, Calif. Business: Pharmaceuticals Ultragenyx and Takeda partnered to develop and commercialize therapies to …

    Published on 6/13/2016
  • Theravance Biopharma, Takeda deal

    Theravance Biopharma Inc. (NASDAQ:TBPH), South San Francisco, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Gastrointestinal Theravance granted Takeda worldwide rights to develop and …

    Published on 6/13/2016
  • Ulster, Avellino Labs deal

    Ulster University, Belfast, U.K. Avellino Labs, Menlo Park, Calif. Business: Ophthalmic The university and Avellino partnered to develop gene therapy technology and create a therapeutic platform to treat hereditary …

    Published on 6/13/2016
  • 4SC, Link Health deal

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Link Health Group, Guangzhou, China Business: Cancer 4SC granted Link Health exclusive rights to develop and commercialize 4SC-205 in Taiwan and China, including Hong …

    Published on 6/6/2016
  • AstraZeneca, Gruenenthal deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Gruenenthal Group, Aachen, Germany Business: Endocrine/Metabolic AstraZeneca granted Gruenenthal exclusive rights to Zurampic lesinurad and a fixed-dose combination of …

    Published on 6/6/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993